Sanofi SA · EURONEXT:SAN

Sanofi SA — Investor Day (March 2022)

4 slides from Sanofi SA's investor day presentation, Mar 29, 2022

1. Slide 1: Scientific references - Immunology Investor Event

   Scientific references - Immunology Investor Event MARCH 29, 2022 AMLITELIMAB ATOPIC PHASE 2A Weidinger S, Cork M, Reich A, Bieber T, Gilbert S, Brennan N, Wilson R, Quaratino S, Porter- EADV 2021 SLIDES DERMATITIS Brown, B. A Phase 2a study of KY1005, a novel non-depleting anti-OX40Ligand (OX40L) mA

2. Slide 2: Eosinophilic Esophagitis, Nasal Polyps, Asthma references

   EOSINOPHILIC TREET Dellon ES, Rothenberg ME, Collins MH, Hirano I, Chehade M, Bredenoord AJ, Lucendo AJ, Spergel UEG 2021 ESOPHAGITIS PHASE 3 JM, Zhao Q, Hamilton JD, Mujumdar U, Kamat S, Mannent LP, Akinlade B, Laws E, Amin N, TRIAL Shumel B, Rowe PJ, Deniz Y, Jacob-Nara JA, Patel K, Maloney J, Mas

3. Slide 3: Atopic Dermatitis references

   ATOPIC AD OLE Wollenberg A, Beck L, Deleuran MS, Blauvelt A, Thyssen J, de Bruin-Weller M, Chen Z, Khokhar F, https://doi.org/10.101 DERMATITIS TRIAL Rodriguez-Marco A, Levit N. Safety of Long-Term Dupilumab Treatment in Adults with Moderate- 6/j.jaci.2021.12.074 to-Severe Atopic Dermatitis up to 17

4. Slide 4: Atopic Dermatitis, Itepekimab, Rilzabrutinib references

   ATOPIC CHRONOS Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp https://doi.org/10.101 DERMATITIS PHASE 3 KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski 6/s0140- TRIAL JC, Ettler K, Kemény L, Zhu X, Akinlad

Sanofi — Investor Day (March 2022) on 6ix